

CONTENTS

<i>Preface</i>	(v)
<i>Contributors</i>	(vii)

Chapter – 1

Transdermal Delivery Systems

1.1 Introduction.....	1
1.2 Definition.....	2
1.2.1 Advantages	2
1.2.2 Disadvantages.....	3
1.3 The Skin.....	3
1.4 Transdermal Delivery Pathways	5
1.4.1 Factors Affecting Transdermal Permeability	7
1.4.1.1 Physico-chemical properties of Penetrant molecule	7
1.4.1.2 Physico chemical properties of drug delivery systems.....	9
1.4.1.3 Physiological and pathological conditions of the skin.....	9
1.4.2 Strategies for the Enhancement of Transdermal Permeation.....	12
1.4.2.1 General aspects.....	12
1.4.2.2 Physical methods.....	13
1.4.2.3 Chemical penetration enhancers.....	15
1.4.3 Basic components of Transdermal Drug Delivery Systems	15.
1.4.3.1 Drug.....	15
1.4.3.2 Polymer	15
1.4.3.3 Permeation enhancers.....	16
1.4.3.4 Other excipients.....	16
1.5 Types of Transdermal Drug Delivery Systems.....	20
1.5.1 Reservoir system	20
1.5.2 Matrix systems-drug in adhesive system.....	21
1.5.3 Matrix-dispersion system	21
1.5.4 Micro reservoir systems	21

1.6	General Methods for the Evaluation of TDDS	26
1.6.1	<i>In vitro</i> Drug Release Study	26
1.6.2	Adhesive Properties.....	27
1.6.2.1	Peel adhesion properties	28
1.6.3	<i>Ex vivo</i> Evaluation.....	29
1.6.3.1	Skin models	29
1.6.3.2	Permeation parameters	33
1.6.3.3	Skin irritation and sensitization study ..	33
1.7	Case Study	36
1.7.1	Development of Carvedilol Transdermal Patches: Evaluation of Physicochemical, <i>Ex vivo</i> and Mechanical Properties	36
1.7.1.1	Introduction-selection criteria for drug.....	36
1.7.1.2	Materials and Methods	36
1.8	Evaluation of Transdermal systems.....	37
1.8.1	Weight and Thickness Variation Studies	37
1.8.2	Drug Content	38
1.8.3	Preparation of Rat Abdominal Skin	38
1.8.4	<i>Ex vivo</i> Permeation Studies	38
1.8.5	Moisture Absorption Study	40
1.8.6	Moisture Content.....	40
1.8.7	Water Vapor Transmission (WVT) Studies	40
1.8.8	Measurement of Mechanical Properties	40
1.8.9	Stability Studies.....	41
1.8.10	Drug–Polymer Interaction Study.....	41
1.9	Results and discussion	41
1.9.1	Weight, Thickness Variation and Drug Content	41
1.9.2	<i>In vitro</i> Release Studies	42
1.9.3	<i>Ex vivo</i> Permeation Studies	43
1.9.4	Moisture Content and Moisture Absorption Studies	44
1.9.5	Water Vapor Transmission (WVT) Study.....	46

1.9.6 Mechanical Properties	46
1.9.7 Drug–Polymer Interaction Study.....	48
1.9.8 Stability Study	49
References.....	49

Chapter – 2

Oral Disintegrating Tablets (ODT)

2.1 Introduction.....	57
2.2 Ideal Properties of ODTs	58
2.3 Advantages of ODTs	59
2.4 Limitations of ODTs.....	60
2.5 Challenges to Develop ODT	60
2.6 Selection of Drug Candidates for ODTs	60
2.7 Selection of Superdisintegrants.....	61
2.8 Formulation Aspects in Developing ODTs.....	61
2.9 Techniques in Preparation of Orally Disintegrating	62
2.9.1 Freeze-Drying or Lyophilization.....	62
2.9.2 Spray Drying	63
2.9.2.1 Molding	63
2.9.3 Phase Transition Process	65
2.9.4 Melt Granulation	65
2.9.5 Sublimation	65
2.9.6 Mass-Extrusion.....	67
2.9.7 Cotton Candy Process	67
2.9.8 Direct Compression.....	68
2.9.8.1 Superdisintegrants	69
2.9.8.2 Sugar based excipients	69
2.9.9 Nanonization	69
2.9.10 Effervescent Method	69
2.10 Patented Technologies for.....	70
2.10.1 Zydis.....	71
2.10.2 Lyoc.....	72
2.10.3 Orasolv Technology	72

2.10.4	Durasolv Technology	73
2.10.5	Wowtab Technology	73
2.10.6	Flashtab Technology	74
2.10.7	Frosta Technology	74
2.10.8	Advatab	74
2.10.9	Flash Dose	75
2.10.10	Oraquick Technology	75
2.10.11	Nanocrystal Technology.....	76
2.10.12	Pharmaburst.....	77
2.10.13	Fast Melt.....	77
2.10.14	Multiflash	77
2.11	Surface Disintegrants in ODTs	77
2.11.1	Role of Superdisintegrants in ODTs.....	77
2.11.2	Mechanism of Superdisintegrants	78
2.11.2.1	Swelling.....	78
2.11.2.2	Porosity and capillary action (Wicking).....	78
2.11.2.3	Due to disintegrating particle/ particle repulsive forces.....	79
2.11.2.4	Due to deformation.....	79
2.11.2.5	Because of heat of wetting (air expansion).....	79
2.11.2.6	Due to release of gases	80
2.11.2.7	By enzymatic reaction	80
2.12	Preformulation Studies	86
2.12.1	Bulk Density (Db)	86
2.12.2	Tapped Density (Dt).....	86
2.12.3	Carr's index (or) % Compressibility	87
2.12.4	Hausner Ratio	87
2.12.5	Angle of Repose	87
2.13	<i>In vitro</i> studies of Orally Disintegrating Tablets	88
2.13.1	Weight Variation	88
2.13.2	Thickness.....	89

2.13.3	Hardness and Friability	89
2.13.3.1	Hardness	89
2.13.3.2	Friability	90
2.13.4	Wetting Time and Water Absorption Ratio.....	90
2.13.5	Assay	91
2.13.6	FT- IR Studies	91
2.13.7	Determination of Disintegration Time of ODTs	92
2.13.8	<i>In vitro</i> Determination of Disintegration Time.....	92
2.13.8.1	Modified US pharmacopoeia method...	92
2.13.8.2	Texture analyzer method	93
2.13.8.3	CCD camera method	93
2.13.8.4	Rotary-shaft method	94
2.13.8.5	Sieve method	95
2.13.9	<i>In vivo</i> Determination of Disintegration Time of ODTs.....	95
2.13.10	Dissolution Testing.....	95
2.13.11	Taste Masking	96
2.14	Patient Counseling in Effective Use of ODT.....	97
2.15	Case Study	98
2.15.1	Formulation and Evaluation of Orally Disintegrating	98
2.16	Abstract.....	98
2.16.1	Purpose	98
2.16.2	Methods	98
2.16.3	Results	99
2.16.4	Conclusion.....	99
2.17	Keywords	99
2.18	Introduction.....	99
2.19	Materials and Methods.....	100
2.20	Development of Buspirone ODTs-Evaluation of Granulation Technique	100
2.20.1	Wet Granulation Technique	100
2.20.2	Freeze Drying Method.....	102

2.21 Physicochemical Evaluation	102
2.21.1 Weight and Thickness Variation	102
2.21.2 Assay of the Tablets	102
2.21.3 Wetting Time and Water Absorption Ratio (R) ...	102
2.21.4 <i>In vitro</i> Disintegration Time	103
2.21.5 <i>In vitro</i> Release Studies	103
2.21.5.1 Results and discussion.....	103
2.21.6 Weight, Thickness and Drug Uniformity	104
2.21.7 Wetting Time.....	104
2.21.8 Water Absorption Ratio.....	104
2.21.9 Disintegration of ODTs	105
2.21.10 Correlation between ‘R’ and ‘DT’	107
2.21.11 <i>In vitro</i> Dissolution.....	107
2.21.11.1 Conclusion.....	107
References.....	108

Chapter – 3

Resealed Erythrocytes

3.1 Introduction.....	112
3.2 Advantages of Erythrocytes in Drug Delivery.....	112
3.3 Drawbacks of Erythrocytes in Drug Delivery.....	113
3.4 Fundamentals of Erythrocytes	114
3.5 Source, Fractionation and Isolation of Erythrocytes.....	116
3.6 Methods of Drug Loading.....	116
3.6.1 Hypotonic Haemolysis	116
3.6.2 Use of Red Cell Loader	117
3.6.3 Hypotonic Dilution.....	117
3.6.4 Hypotonic Preswelling	118
3.6.5 Hypotonic Dialysis	118
3.6.6 Isotonic Osmotic Lysis	119
3.6.7 Chemical Perturbation of the Membrane	120
3.6.8 Electro-Insertion or Electroencapsulation	120
3.6.9 Entrapment by Endocytosis	122
3.6.10 Loading by Electric Cell Fusion.....	122

3.7 <i>In vitro</i> Characterization	122
3.7.1 Drug Content	124
3.7.2 <i>In vitro</i> Drug Release and Hemoglobin Release ..	124
3.7.3 Percent Cell Recovery	125
3.7.4 Morphology	125
3.7.5 Osmotic Fragility.....	126
3.7.6 Osmotic Shock	126
3.7.7 Turbulence Shock.....	126
3.7.8 Determination of Entrapped Magnetite	126
3.7.9 Erythrocyte Sedimentation Rate (ESR).....	127
3.7.10 The Zeta Sedimentation Ratio	127
3.7.11 Miscellaneous	127
3.8 <i>In vitro</i> Storage	127
3.9 <i>In vivo</i> Life Span.....	128
3.10 Therapeutic Applications of Resealed Erythrocytes in Drug Delivery	128
3.10.1 Erythrocytes as Drug Carriers	128
3.10.1.1 Antineoplastic Drugs	128
3.10.1.2 Angiotensin-converting enzyme (ACE) inhibitors.....	131
3.10.1.3 Anti-infective agents	132
3.10.1.4 Systemic corticosteroids	133
3.10.1.5 Antioxidant drugs	133
3.10.1.6 Iron chelators.....	134
3.10.1.7 Prodrugs.....	134
3.10.2 Applications of Carrier Erythrocytes in Delivery of Biopharmaceuticals	134
3.10.2.1 Amino acid-based biopharmaceuticals	138
3.10.3 Therapeutic Enzymes	142
3.10.4 Nucleic Acid-based Biopharmaceuticals.....	143
3.10.4.1 Oligonucleotides, polynucleotides and their analogues	145

3.10.5 Immunogenic Biopharmaceuticals	146
3.10.5.1 Model antigens	146
3.10.5.2 Bacterial toxoids.....	147
3.10.5.3 Viral subunit vaccines	147
3.10.5.4 Cancer vaccines.....	148
3.11 Other Applications.....	148
3.11.1 Transport of O	148
3.11.2 New Dosage Forms	149
3.11.3 Encapsulation of Paramagnetic Erythrocytes.....	149
3.11.4 Encapsulation of MRI Contrast Agents.....	149
3.11.5 Study of Metabolism in the Red Cell	149
3.11.6 Fused Erythrocytes	150
3.12 Novel Approaches.....	150
3.12.1 Erythroosomes.....	150
3.12.2 Nanoerythroosomes.....	150
3.13 Conclusions.....	150
References.....	151

Chapter – 4

Polymeric Nanoparticles

4.1 Introduction.....	156
4.2 Rationale for the Drug Delivery Applications of Polymeric Nanoparticles	157
4.3 Polymers used in the Nanoparticle Preparation	162
4.3.1 PLA and PLGA	162
4.3.2 Polycaprolactone	164
4.3.3 Chitosan.....	165
4.3.4 Gelatin	166
4.3.5 Albumin.....	167
4.3.6 Poly-Alkyl-Cyano-Acrylates	169
4.3.7 Copolymers	169
4.4 Opsonization and Physical Properties of the NPs: the Important Determinants of Performance of the Nanoparticles	170

4.5 Influence of Drug Loading and Drug Release from Nanoparticles on the Performance of Polymeric Nanoparticles.....	172
4.6 Methods of Preparation of Drug Loaded Nanoparticles	174
4.6.1 Two Step Procedure: Formation of Polymer Nanoparticles from an Emulsion	174
4.6.2 Obtaining Nanoparticles by Gelation of Emulsion Droplets.....	178
4.6.3 Inducing Nanoparticle Formation by <i>In situ</i> Polymerization	178
4.6.3.1 Polymerization of alkylcyanoacrylates	178
4.6.3.2 Obtaining nanocapsules by interfacial polycondensation reactions	179
4.6.3.3 One step procedures	180
4.7 Pilot Scale Production of Nanoparticles	181
4.8 Purification of Nanoparticle Suspensions	182
4.9 Sterilization of Nanoparticle Suspensions	182
References.....	183

Chapter – 5

Bioadhesive Drug Delivery System: A Current Status

5.1 Introduction.....	185
5.2 Bioadhesion and Mucoadhesion	186
5.2.1 Definition.....	186
5.2.2 Mechanisms of Bioadhesion.....	187
5.2.2.1 Chemical Bonds	188
5.2.2.2 Mechanical or Physical Bonds	188
5.2.3 Theories of Bioadhesion.....	188
5.2.3.1 Electronic theory	189
5.2.3.2 The adsorption theory.....	189
5.2.3.3 The wetting theory.....	189
5.2.3.4 The diffusion theory	190
5.2.3.5 The fracture theory	191

5.3 Mucoadhesive Polymers	192
5.3.1 Characteristics of an Ideal Mucoadhesive Polymer	192
5.3.2 Molecular Characteristics	193
5.3.3 Factors Affecting Mucoadhesion	196
5.3.3.1 Polymer related factors.....	196
5.3.3.2 Environment related factors	197
5.3.3.3 Physiological factors	198
5.3.4 Novel Second-Generation Mucoadhesives.....	199
5.3.4.1 Lectins	199
5.3.4.2 Bacterial adhesions	200
5.3.4.3 Thiolated polymers	200
5.4 Classification of Bioadhesive Dosage Forms	201
5.4.1 Drug Delivery via Oral Mucosa	201
5.4.2 Bioadhesive Oral Drug Delivery	206
5.4.2.1 Oral gastrointestinal bioadhesive dosage form applications.....	207
5.4.3 Vaginal Drug Delivery	208
5.4.4 Nasal Bioadhesive Drug Delivery	210
5.4.5 Ocular Drug Delivery	215
5.5 Evaluation Methods to Study Mucoadhesion	217
5.5.1 <i>In vitro/Ex vivo</i> Methods	217
5.5.1.1 Methods based on measurement of tensile strength.....	217
5.5.1.2 Methods based on measurement of shear strengths	219
5.5.1.3 Adhesion weight method.....	219
5.5.1.4 Fluorescent probe method	219
5.5.1.5 Flow channel method	220
5.5.1.6 Mechanical spectroscopic method.....	220
5.5.1.7 Falling liquid film method.....	220
5.5.1.8 Colloidal gold staining method	220
5.5.1.9 Viscometric method.....	221
5.5.1.10 Electrical conductance.....	221

5.5.2 <i>In vivo</i> Methods	221
5.5.2.1 Use of radioisotopes	221
5.5.2.2 Use of gamma scintigraphy	221
5.5.2.3 Use of pharmacoscintigraphy	222
5.5.2.4 Use of Electron paramagnetic resonance (EPR) oximetry	222
5.5.2.5 X-ray studies.....	222
5.5.2.6 Isolated-loop technique	222
5.5.2.7 Bioavailability studies	223
5.6 Research Case Studies for Bioadhesive Drug Delivery System.....	223
5.6.1 Case study of Bioadhesive oral Multiple Unit Systems (MUS)	223
5.6.1.1 Introduction	223
5.6.1.2 Methods	224
5.6.1.3 Results and Discussion	228
5.6.1.4 Remarks of the case study	233
5.6.2 Case study of Bioadhesive Matrix Tablets	233
5.6.2.1 Drug selection criteria	233
5.6.2.2 Polymer selection criteria	233
5.6.2.3 Methods	233
5.6.2.4 Results and Discussion	236
5.6.2.5 Remarks of the case study	241
5.7 Conclusion	241
References.....	242

Chapter – 6

Liver Targeting Drug Delivery

6.1 Introduction.....	267
6.2 Anatomical Background of Liver Relevant to Drug Delivery	267
6.3 Liver Disorders in which Drug Targeting Can be Applied...	270
6.3.1 HBV Infection	271
6.3.2 Liver Fibrosis/Cirrhosis.....	275
6.3.3 Hepatocellular Cancer (HCC)	278

6.4 Current clinical Treatments for Liver Disorders and Challenges.....	280
6.4.1 Anti-HBV Therapy.....	280
6.4.2 Liver Fibrosis Therapy	281
6.4.3 Anti-HCC Therapy	282
6.5 Liver Specific Targeting Strategies	283
6.5.1 Antibody Mediated Targeting	285
6.5.2 Viral Mediated Targeting	286
6.5.3 Organ Isolation.....	286
6.5.4 Targeting using Ligands.....	287
6.5.4.1 Synthetic ligand mediated targeting ...	287
6.5.4.2 Natural ligand mediated targeting	289
6.5.5 Targeting Using Particulates	290
6.5.5.1 Targeting using microparticles.....	290
6.5.5.2 Targeting using liposomes.....	291
6.5.5.3 Targeting using nanotherapeutics.....	299
6.5.5.4 Targeting using micellar nanoparticles.....	303
6.5.5.5 Targeting using miscellaneous systems	304
6.6 Conclusions.....	305
References.....	306

Chapter – 7

Monoclonal Antibodies

7.1 Introduction.....	317
7.2 Production of MABs.....	319
7.2.1 <i>In vivo</i> Production of Monoclonal Antibody	321
7.2.1.1 Batch tissue-culture methods.....	321
7.2.1.2 Semipermeable-membrane-based systems	322
7.2.2 <i>In vivo</i> Method.....	323
7.3 Purification of Monoclonal Antibodies	324
7.4 Chimeric and Humanized Monoclonal Antibodies (suffixes -ximab, -zumab respectively).....	326

7.5 Recombinant Antibodies.....	328
7.6 Nomenclature of Monoclonal Antibodies.....	329
7.6.1 Stem.....	329
7.6.2 Substem for Origin/Source.....	330
7.6.3 Substem for Target.....	330
7.6.4 Prefix.....	331
7.6.5 Additional Words.....	331
7.7 Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies.....	332
7.7.1 Factors that can affect the PK, Biological Activity or Immunogenicity of Therapeutic Proteins.....	333
7.8 Applications of Monoclonal Antibodies.....	337
7.8.1 Monoclonal Antibodies in Diagnostic Applications.....	337
7.8.2 Monoclonal Antibodies in Therapeutic Applications.....	338
7.9 FDA Approved Therapeutic Antibodies.....	346
7.10 Bispecific Monoclonal Antibodies (BsMAb).....	348
7.10.1 Structure.....	348
7.10.2 Mechanism of Action.....	349
7.10.3 Advantages Over Monoclonal Antibodies.....	349
7.11 Conclusion.....	349
7.12 Case Study.....	350
References.....	358

Chapter – 8

Hot Melt Extrusion

8.1 Introduction.....	365
8.2 HME Principle and Equipment.....	367
8.2.1 Ram Extrusion.....	367
8.2.2 Screw Extrusion.....	368
8.2.3 Down Stream Equipment.....	371
8.2.4 Melt-Extrusion Process.....	372

8.3	Materials used in HME Process	373
8.3.1	Carriers	373
8.3.2	Plasticizers.....	374
8.3.3	Processing Aids	375
8.3.4	Active Pharmaceutical Ingredients (API).....	376
8.4	Characteristics of Hot-Melt Extruded Dosage Forms.....	377
8.4.1	Chemical Stability of the Active During Extrusion.....	377
8.4.2	Thermal and Crystalline Properties of the Extrudates.....	377
8.4.3	Thermogravimetric Analysis (TGA)	378
8.4.4	Differential Scanning Calorimetry (DSC) Analysis.....	379
8.4.5	Scanning Electron Microscopy (SEM) Analysis.....	379
8.4.6	Fourier Transformation-infrared	379
8.4.7	X-ray Powder Diffraction (XRPD) Analysis.....	380
8.4.8	Mechanical Properties Testing	380
8.4.9	Bioadhesion	380
8.4.10	Dissolution Studies.....	381
8.5	Pharmaceutical Applications	382
8.5.1	Oral Drug Delivery.....	382
8.5.1.1	Immediate release	382
8.5.1.2	Sustained release	385
8.5.1.3	Enteric release	387
8.5.1.4	Targeted release.....	390
8.5.2	Transdermal Drug Delivery.....	391
8.5.3	Buccal Drug Delivery.....	392
8.5.4	Transungual Drug Delivery	394
8.5.5	Implants.....	394
8.6	Oral Transmucosal Delivery of Domperidone from Immediate Release Hot-Melt Extruded Films – A Case Study	395
8.6.1	Experimental	396
8.6.1.1	Preparation of DOM hot-melt extruded films.....	396

8.6.2	Thermal Gravimetric Analysis (TGA)	397
8.6.3	Differential Scanning Calorimetry (DSC) Analysis	397
8.6.4	Evaluation of Physicochemical Properties	397
8.6.5	Measurement of Mechanical Properties	397
8.6.6	<i>In vitro</i> Bioadhesion and <i>In vivo</i> Residence Time Measurement	398
8.6.7	<i>In vitro</i> Drug Release Study	399
8.6.8	<i>Ex vivo</i> Drug Permeation from HME DOM2 Film through Porcine Buccal Membrane	399
8.6.9	<i>In vivo</i> Bioavailability Study in Humans.....	399
8.6.10	<i>Ex vivo–In vivo</i> Correlation	400
8.6.11	Stability Studies.....	400
8.7	Results and Discussion	400
8.7.1	Thermogravimetric Analysis (TGA)	400
8.7.2	Differential Scanning Calorimetry (DSC) Analysis	400
8.7.3	Physicochemical Properties of HME DOM Formulations	402
8.7.4	Mechanical Properties of Films.....	403
8.7.5	<i>In vitro</i> Bioadhesion and <i>In vivo</i> Residence Time Measurement.....	403
8.7.6	<i>In vitro</i> Release from HME DOM Patches.....	403
8.7.7	<i>Ex vivo</i> Permeation of DOM from HME DOM2 Film	404
8.7.8	<i>In vivo</i> Bioavailability Studies.....	405
8.7.9	<i>Ex vivo- In vivo</i> Correlation.....	407
8.8	Stability Study.....	408
8.9	Current Marketed Products	409
8.10	Conclusions and Future Prospects	409
8.11	Acknowledgements.....	410
	References.....	410

Chapter – 9**Pulmonary Drug Delivery System**

9.1 Introduction.....	419
9.1.1 Advantages	420
9.1.2 Disadvantages.....	421
9.1.3 Applications.....	421
9.2 Anatomy and Physiology of Airways of Lungs.....	421
9.2.1 Structure	421
9.2.2 Evaluation of Airway Physiology and Function...	424
9.3 Mechanisms of Deposition of Particles	426
9.3.1 The Aerodynamic Diameter	427
9.3.2 Factors Affecting Respiratory Deposition.....	428
9.3.3 The Principal Mechanisms Involved in the Deposition of Aerosols	428
9.3.3.1 Impaction.....	429
9.3.3.2 Sedimentation.....	429
9.3.3.3 Interception.....	429
9.3.3.4 Diffusion.....	430
9.4 Absorption of Drug Particles	431
9.5 Pulmonary Drug Delivery Devices.....	432
9.5.1 Nebulizers.....	432
9.5.2 Metered Dose Inhalers (MDIs).....	434
9.5.2.1 Containers.....	435
9.5.2.2 Propellants	435
9.5.2.3 Metering valve.....	438
9.5.3 Actuator	439
9.5.4 Dry Powder Inhalers (DPIs).....	440
9.6 Recent Advances in Pulmonary Drug Delivery Formulations	442
9.6.1 Large, Porous Particles	443
9.6.2 Adjuvants.....	443
9.6.3 Liposomes	444
9.6.4 Micelles	445
9.6.5 Microemulsions	446
9.6.6 Microparticles and Nanoparticles.....	447

9.7 Recent Advances in Pulmonary Drug Delivery Devices	449
9.7.1 Advances in MDIs	449
9.7.2 Advances in DPIs	451
9.7.3 Advances in Nebulizers	452
9.8 Upcoming Trends: A Peep into the Future	453
References	455

Chapter – 10

Intracellular Drug Delivery Systems

10.1 Introduction	462
10.2 Cellular Internalization Processes	465
10.3 Mechanisms of Intracellular Delivery	465
10.3.1 Passive Transport	465
10.3.2 Endocytosis	465
10.3.2.1 Endocytic mechanisms for directed targeting	469
10.4 Carriers for Targeted Drug Delivery	486
10.5 Modalities of Macromolecular Therapeutic Delivery	488
10.5.1 Nondegradative Directed Systems	489
10.5.2 Targeted Complexes for Lysosomal Delivery	489
10.6 Drug Delivery Approaches to Intracellular Targeting	490
10.6.1 Designing ICDDS	490
10.6.1.1 Viral Vectors	491
10.6.1.2 Liposomes, polymer conjugates, cationic polymers, and lipids	491
10.6.1.3 Protein transduction domains	493
10.6.1.4 Nanoparticles	493
10.6.1.5 Hydrogels	495
10.6.1.6 Biological peptides/proteins	496
10.6.1.7 DNA dendrimers	496
10.7 Recent Advances in Intracellular Drug Delivery	498
10.8 Conclusion	501
References	501